CPA
VERV

Capital Performance Advisors’s Verve Therapeutics VERV Stock Holding History

Capital Performance Advisors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-141
Closed -$682 – 2594
2024
Q3 		$682 Buy
+141
New +$819 ﹤0.01% 2103

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital Performance Advisors's VERV Position: Q4 2024 in Review

Capital Performance Advisors sold out of Verve Therapeutics (VERV) in Q4 2024, closing a stake of 141 shares — an estimated $682 sold.

Capital Performance Advisors first reported a position in VERV in Q3 2024 and held it in 1 quarter. The position peaked at $682 in Q3 2024. 166 funds tracked by Wall St. Rank hold VERV as of Q4 2024.

  • Capital Performance Advisors reported no remaining Verve Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 141 Verve Therapeutics shares in Q4 2024, an estimated $682.
  • Capital Performance Advisors first reported a position in Verve Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Verve Therapeutics position peaked at $682 in Q3 2024.
  • 166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.